Yu-Ling Shi (Yuling Shi)

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 60

Top Venues

Dermatology and therapy

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Dermatologic therapy

Drug safety

Tenth People's Hospital of Tongji University

Second Military Medical University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Tenth People's Hospital of Tongji University Feb 02 2007 - Aug 01 2019

China

director :: dermatology

Education History

Second Military Medical University Sep 01 2007 - Jun 28 2010

China

PHD :: Dermatology

Tongji University Sep 01 2001 - Jul 31 2004

China

MSC :: Dermatology

Tongji University Sep 01 1991 - Jul 31 1996

China

BSC :: clinical medicine

Publications

Yu-Ling Shi, Edward Lain, Nicolas Frasson, Ariadna Ortiz Brugués, Aline Stennevin
The Real-World Effectiveness and Tolerability of a Soothing Cream Containing the Postbiotic Aquaphilus dolomiae Extract-G2 for Skin Healing. Dermatology and therapy 14 (3) (2024)
Ying Li, Lin Dang, Chengzhi Lv, Bingjiang Lin, Juan Tao, Nan Yu, Ya Deng, Huiping Wang, Xiaojing Kang, Hui Qin, Rong Chen, Jinnan Li, Yunsheng Liang, Yanhua Liang, Yu-Ling Shi
The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study. Drug safety 47 (7) (2024)
Yu-Ling Shi, Edward Lain, Nicolas Frasson, Ariadna Ortiz Brugués, Aline Stennevin
The Real-World Effectiveness and Tolerability of a Soothing Cream Containing the Postbiotic Aquaphilus dolomiae Extract-G2 for Skin Healing. Dermatology and therapy 14 (3) (2024)
Yu-Ling Shi, Edward Lain, Nicolas Frasson, Ariadna Ortiz Brugués, Aline Stennevin
The Real-World Effectiveness and Tolerability of a Soothing Cream Containing the Postbiotic Aquaphilus dolomiae Extract-G2 for Skin Healing. Dermatology and therapy 14 (3) (2024)
Ying Li, Chengzhi Lv, Lin Dang, Bingjiang Lin, Juan Tao, Chunlei Zhang, Xiaoyong Zhou, Han Ma, Yi Lu, Rong Chen, Jinnan Li, Guanshen Dou, Yunsheng Liang, Yanhua Liang, Yu-Ling Shi
Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study. Dermatology and therapy (2024)
Ying Li, Lin Dang, Chengzhi Lv, Bingjiang Lin, Juan Tao, Nan Yu, Ya Deng, Huiping Wang, Xiaojing Kang, Hui Qin, Rong Chen, Jinnan Li, Yunsheng Liang, Yanhua Liang, Yu-Ling Shi
The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study. Drug safety 47 (7) (2024)
Ying Li, Chengzhi Lv, Lin Dang, Bingjiang Lin, Juan Tao, Chunlei Zhang, Xiaoyong Zhou, Han Ma, Yi Lu, Rong Chen, Jinnan Li, Guanshen Dou, Yunsheng Liang, Yanhua Liang, Yu-Ling Shi
Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study. Dermatology and therapy 14 (4) (2024)
Ying Li, Xiaoyuan Zhong, Dawei Huang, Yu-Ling Shi, Yangfeng Ding
Efficacy and safety of oral abrocitinib monotherapy in pityriasis rubra pilaris. Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Ying Li, Chengzhi Lv, Lin Dang, Bingjiang Lin, Juan Tao, Chunlei Zhang, Xiaoyong Zhou, Han Ma, Yi Lu, Rong Chen, Jinnan Li, Guanshen Dou, Yunsheng Liang, Yanhua Liang, Yu-Ling Shi
Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study. Dermatology and therapy 14 (4) (2024)
Yu-Ling Shi, Edward Lain, Nicolas Frasson, Ariadna Ortiz Brugués, Aline Stennevin
The Real-World Effectiveness and Tolerability of a Soothing Cream Containing the Postbiotic Aquaphilus dolomiae Extract-G2 for Skin Healing. Dermatology and therapy (2024)
Min Wu, Sining Zeng, Yi Zhang, Yanru Liu, Bingbing Li, Xuemei Yi, Yu-Ling Shi, Xiaoping Zhu
Disease Burden and Coping Strategies of Spouses of Patients with Psoriasis: A Qualitative Study. Journal of multidisciplinary healthcare 17 (2024)
Yu-Ling Shi, Edward Lain, Nicolas Frasson, Ariadna Ortiz Brugués, Aline Stennevin
The Real-World Effectiveness and Tolerability of a Soothing Cream Containing the Postbiotic Aquaphilus dolomiae Extract-G2 for Skin Healing. Dermatology and therapy 14 (3) (2024)
Dawei Huang, Xiaoyuan Zhong, Yuxiong Jiang, Luyang Kong, Rui Ma, Jiajing Lu, Ying Li, Yu-Ling Shi
Insulin Resistance Impairs Biological Agents Response in Moderate-to-Severe Plaque Psoriasis: Insights from a Prospective Cohort Study in China. The British journal of dermatology (2024)
Yu-Ling Shi, Edward Lain, Nicolas Frasson, Ariadna Ortiz Brugués, Aline Stennevin
The Real-World Effectiveness and Tolerability of a Soothing Cream Containing the Postbiotic Aquaphilus dolomiae Extract-G2 for Skin Healing. Dermatology and therapy 14 (3) (2024)
Ying Li, Chengzhi Lv, Lin Dang, Bingjiang Lin, Juan Tao, Chunlei Zhang, Xiaoyong Zhou, Han Ma, Yi Lu, Rong Chen, Jinnan Li, Guanshen Dou, Yunsheng Liang, Yanhua Liang, Yu-Ling Shi
Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study. Dermatology and therapy 14 (4) (2024)
Yu-Ling Shi, Edward Lain, Nicolas Frasson, Ariadna Ortiz Brugués, Aline Stennevin
Correction to: The Real-World Effectiveness and Tolerability of a Soothing Cream Containing the Postbiotic Aquaphilus dolomiae Extract-G2 for Skin Healing. Dermatology and therapy (2024)
Ying Li, Chengzhi Lv, Lin Dang, Bingjiang Lin, Juan Tao, Chunlei Zhang, Xiaoyong Zhou, Han Ma, Yi Lu, Rong Chen, Jinnan Li, Guanshen Dou, Yunsheng Liang, Yanhua Liang, Yu-Ling Shi
Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study. Dermatology and therapy 14 (4) (2024)
Dawei Huang, Xiaoyuan Zhong, Yuxiong Jiang, Luyang Kong, Rui Ma, Jiajing Lu, Ying Li, Yu-Ling Shi
Insulin Resistance Impairs Biological Agents Response in Moderate-to-Severe Plaque Psoriasis: Insights from a Prospective Cohort Study in China. The British journal of dermatology (2024)
Min Wu, Sining Zeng, Yi Zhang, Yanru Liu, Bingbing Li, Xuemei Yi, Yu-Ling Shi, Xiaoping Zhu
Disease Burden and Coping Strategies of Spouses of Patients with Psoriasis: A Qualitative Study. Journal of multidisciplinary healthcare 17 (2024)
Min Wu, Sining Zeng, Yi Zhang, Yanru Liu, Bingbing Li, Xuemei Yi, Yu-Ling Shi, Xiaoping Zhu
Disease Burden and Coping Strategies of Spouses of Patients with Psoriasis: A Qualitative Study. Journal of multidisciplinary healthcare 17 (2024)
Ying Li, Lin Dang, Chengzhi Lv, Bingjiang Lin, Juan Tao, Nan Yu, Ya Deng, Huiping Wang, Xiaojing Kang, Hui Qin, Rong Chen, Jinnan Li, Yunsheng Liang, Yanhua Liang, Yu-Ling Shi
The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study. Drug safety 47 (7) (2024)
Yu-Ling Shi, Edward Lain, Nicolas Frasson, Ariadna Ortiz Brugués, Aline Stennevin
The Real-World Effectiveness and Tolerability of a Soothing Cream Containing the Postbiotic Aquaphilus dolomiae Extract-G2 for Skin Healing. Dermatology and therapy 14 (3) (2024)
Ying Li, Lin Dang, Chengzhi Lv, Bingjiang Lin, Juan Tao, Nan Yu, Ya Deng, Huiping Wang, Xiaojing Kang, Hui Qin, Rong Chen, Jinnan Li, Yunsheng Liang, Yanhua Liang, Yu-Ling Shi
The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study. Drug safety (2024)
Ying Li, Lin Dang, Chengzhi Lv, Bingjiang Lin, Juan Tao, Nan Yu, Ya Deng, Huiping Wang, Xiaojing Kang, Hui Qin, Rong Chen, Jinnan Li, Yunsheng Liang, Yanhua Liang, Yu-Ling Shi
The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study. Drug safety 47 (7) (2024)
Yuxiong Jiang, Youdong Chen, Qian Yu, Yu-Ling Shi
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2023)
Ning Yu, Chen Peng, Jing Zhou, Jun Gu, Jinhua Xu, Xia Li, Xinling Bi, Hui Deng, Xin Li, Yangfeng Ding, Yu-Ling Shi
Measurement properties of the Patient Global Assessment numerical rating scale in moderate-to-severe psoriasis. The British journal of dermatology (2023)
Jiajing Lu, Xiaoyuan Zhong, Chunyuan Guo, Li Tang, Ning Yu, Chen Peng, Yangfeng Ding, Xunxia Bao, Jing Zhou, Yu-Ling Shi
TLR7-MyD88-DC-CXCL16 axis results neutrophil activation to elicit inflammatory response in pustular psoriasis. Cell death & disease 14 (5) (2023)
Xin Wang, Yu-Ling Shi, Ye-Qiang Liu
Baricitinib treatment of extragenital lichen sclerosus caused by COVID-19 vaccine. The Australasian journal of dermatology (2023)
Li Ying, Ji Suyun, Liang Yanhua, Liang Yunsheng, Deng Li, Dang Lin, Lv Chengzhi, Lin Bingjiang, Zhang Furen, Shi Wendi, Li Jinnan, Dong Yu, Dou Guanshen, Yu-Ling Shi
Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study. Advances in therapy (2023)
Jiajing Lu, Xiaoyuan Zhong, Chunyuan Guo, Li Tang, Ning Yu, Chen Peng, Yangfeng Ding, Xunxia Bao, Jing Zhou, Yu-Ling Shi
TLR7-MyD88-DC-CXCL16 axis results neutrophil activation to elicit inflammatory response in pustular psoriasis. Cell death & disease 14 (5) (2023)
Yuxiong Jiang, Youdong Chen, Qian Yu, Yu-Ling Shi
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 37 (1) (2023)
Yuxiong Jiang, Youdong Chen, Qian Yu, Yu-Ling Shi
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 37 (1) (2023)
Yuxiong Jiang, Youdong Chen, Qian Yu, Yu-Ling Shi
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 37 (1) (2023)
Chen Peng, Li Tang, Ning Yu, Yangfeng Ding, Yu-Ling Shi
Global, regional, and national burden of urticaria from 1990 to 2019. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Jiajing Lu, Xiaoyuan Zhong, Chunyuan Guo, Li Tang, Ning Yu, Chen Peng, Yangfeng Ding, Xunxia Bao, Jing Zhou, Yu-Ling Shi
TLR7-MyD88-DC-CXCL16 axis results neutrophil activation to elicit inflammatory response in pustular psoriasis. Cell death & disease 14 (5) (2023)
Xingyu Jiang, Rongcan Shi, Rui Ma, Xinyi Tang, Yu Gong, Zengyang Yu, Yu-Ling Shi
The role of microRNA in psoriasis: A review. Experimental dermatology (2023)
Yuxiong Jiang, Youdong Chen, Qian Yu, Yu-Ling Shi
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 37 (1) (2023)
Jiajing Lu, Xiaoyuan Zhong, Chunyuan Guo, Li Tang, Ning Yu, Chen Peng, Yangfeng Ding, Xunxia Bao, Jing Zhou, Yu-Ling Shi
TLR7-MyD88-DC-CXCL16 axis results neutrophil activation to elicit inflammatory response in pustular psoriasis. Cell death & disease 14 (5) (2023)
Lian Cui, Rui Ma, Jiangluyi Cai, Chunyuan Guo, Zeyu Chen, Lingling Yao, Yuanyuan Wang, Rui Fan, Xin Wang, Yu-Ling Shi
RNA modifications: importance in immune cell biology and related diseases. Signal transduction and targeted therapy 7 (1) (2022)
Ying Li, Jia-Jing Lu, Xiao-Yuan Zhong, Ying-Yuan Yu, Ning Yu, Yu Wang, Xue-Mei Yi, Yang-Feng Ding, Yu-Ling Shi
Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study. Clinical, cosmetic and investigational dermatology 15 (2022)
Xiaoyuan Zhong, Ying Li, Yunlu Gao, Ying Zhang, Jiajing Lu, Ning Yu, Yangfeng Ding, Yu-Ling Shi
Pustular psoriasis appearing in a Chinese woman treated with dupilumab for atopic dermatitis: A case report. Dermatologic therapy 35 (11) (2022)
Youdong Chen, Yifan Hu, Xue Zhou, Zihan Zhao, Qian Yu, Zeyu Chen, Yuanyuan Wang, Peng Xu, Zengyang Yu, Chunyuan Guo, Xilin Zhang, Yu-Ling Shi
Human umbilical cord-derived mesenchymal stem cells ameliorate psoriasis-like dermatitis by suppressing IL-17-producing γδ T cells. Cell and tissue research 388 (3) (2022)
Hui Qin, Jiajing Lu, Xuemei Yi, Yangfeng Ding, Yu-Ling Shi
Secukinumab treatment for a psoriasis patient co-infected with HIV and latent tuberculosis: A case report. The Journal of dermatology 49 (11) (2022)
Jiajing Lu, Yu Wang, Ying Li, Yu Gong, Yangfeng Ding, Yu-Ling Shi
Comparative Study on the Clinical Efficacy and Safety of Acitretin and MTX in the Treatment of Pustular Psoriasis by TLR7/MyD88/CXCL16 Pathway. Applied bionics and biomechanics 2022 (2022)
Xue Zhou, Youdong Chen, Lian Cui, Yu-Ling Shi, Chunyuan Guo
Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell death & disease 13 (1) (2022)
Huaiji Wang, Zihan Zhao, Chenghao Wu, Xiaowen Tong, Yu-Ling Shi, Shunjie Chen
Microneedle Patch Delivery of Methotrexate-Loaded Albumin Nanoparticles to Immune Cells Achieves a Potent Antipsoriatic Effect. International journal of nanomedicine 17 (2022)
Ying Li, Jiajing Lu, Rongfen Chen, Yu Wang, Yangfeng Ding, Shuang Xu, Ying Zou, Xuemei Yi, Yu-Ling Shi
The efficacy and safety of dupilumab for the treatment of atopic dermatitis among Chinese patients in clinical practice: A single-center retrospective study. Dermatologic therapy 35 (5) (2022)
Yang Yang, Shaoqiong Xie, Wencheng Jiang, Suwei Tang, Yu-Ling Shi
Discovering Novel Biomarkers Associated with the Pathogenesis of Psoriasis: Evidence from Bioinformatic Analysis. International journal of general medicine 15 (2022)
Xilin Zhang, Peng Xu, Jiajing Lu, Yangfeng Ding, Jun Gu, Yu-Ling Shi
Erythrokeratodermia variabilis et progressiva due to a novel mutation in GJB4. Experimental dermatology (2021)
Yu Gong, Ke Xue, Yifan Hu, Rong Wei, Ye-Qiang Liu, Hua Cao, Yu-Ling Shi
A Case of Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type with Dermatomyositis. Annals of dermatology 33 (2) (2021)
Nan Yang, Zeyu Chen, Xilin Zhang, Yu-Ling Shi
Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 35 (4) (2021)
Chen Peng, Yifan Hu, Wenjuan Chen, Yangfeng Ding, Xingzi Li, Ning Yu, Jiajing Lu, Yu-Ling Shi
A randomized prospective study of different dose regimens using the 308-nm excimer laser in the treatment of palmoplantar pustulosis. Dermatologic therapy 34 (5) (2021)
Ning Yu, Ying Li, Yangfeng Ding, Yu-Ling Shi
Combination therapy with acitretin and glycyrrhizin in generalized pustular psoriasis with liver test abnormalities: A case series. Dermatologic therapy 33 (3) (2020)
Yang Su, Jinling Huang, Xiaohong Zhao, Huiping Lu, Wang Wang, Xuexian O Yang, Yu-Ling Shi, Xiaohu Wang, Yuping Lai, Chen Dong
Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation. Science immunology 4 (36) (2020)
Zihan Zhao, Youdong Chen, Yu-Ling Shi
Microneedles: a potential strategy in transdermal delivery and application in the management of psoriasis. RSC advances 10 (24) (2020)
Zeyu Chen, Yifan Hu, Yu Gong, Xilin Zhang, Lian Cui, Rongfen Chen, Yingyuan Yu, Qian Yu, Youdong Chen, Hongyue Diao, Jia Chen, Yuanyuan Wang, Yu-Ling Shi
Interleukin-33 alleviates psoriatic inflammation by suppressing the T helper type 17 immune response. Immunology 160 (4) (2020)
Yu Gong, Zeyu Chen, Yue'e Ma, Weiwei Jiang, Yifan Hu, Yu-Ling Shi
Cutaneous phaeohyphomycosis caused by Pyrenochaeta unguis-hominis in a diabetic patient: A case report. The Australasian journal of dermatology 61 (2) (2019)
Yifan Hu, Zeyu Chen, Yu Gong, Yu-Ling Shi
A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis. Clinical drug investigation 38 (3) (2018)
Zeyu Chen, Yu Gong, Yu-Ling Shi
Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis. Clinical drug investigation 37 (10) (2018)
Yu-Ling Shi, Qian Yu, Zeyu Chen, Yu-Ling Shi
Management of pediatric psoriasis with acitretin: A review. Dermatologic therapy 31 (1) (2017)

Yu-Ling Shi.css-eqlu8i{font-size:small;padding-left:4px;} (Yuling Shi)

Publication Activity (10 Years)

Top Topics

Top Venues

Yu-Ling Shi (Yuling Shi)